CryoLife, Inc. Working Capital

Working Capital of CRY for past 10 years: annual, quarterly and twelve month trailing (TTM) including Working Capital growth rates and interactive chart. Working capital, also known as net working capital (NWC), is the difference between a company’s current assets, such as cash, accounts receivable (customers’ unpaid bills) and inventories of raw materials and finished goods, and its current liabilities, such as accounts payable. Net operating working capital is a measure of a company's liquidity and refers to the difference between operating current assets and operating current liabilities. In many cases these calculations are the same and are derived from company cash plus accounts receivable plus inventories, less accounts payable and less accrued expenses. Working capital is a measure of a company's liquidity, operational efficiency and its short-term financial health. If a company has substantial positive working capital, then it should have the potential to invest and grow. If a company's current assets do not exceed its current liabilities, then it may have trouble growing or paying back creditors, or even go bankrupt.


Highlights and Quick Summary

  • Working Capital for the quarter ending March 30, 2021 was $178 Million (a 29.14% increase compared to previous quarter)
  • Year-over-year quarterly Working Capital decreased by -12.64%
  • Annual Working Capital for 2020 was $138 Million (a 25.47% increase from previous year)
  • Annual Working Capital for 2019 was $110 Million (a -1.64% decrease from previous year)
  • Annual Working Capital for 2018 was $111 Million (a 10.73% increase from previous year)
Visit stockrow.com/CRY for comprehensive keystats, realtime prices, income statement, balance sheet, cash flow statement with 10 years of data, and state-of-the-art screener.

Historical Working Capital of CryoLife, Inc.

Most recent Working Capitalof CRY including historical data for past 10 years.

Interactive Chart of Working Capital of CryoLife, Inc.

CryoLife, Inc. Working Capital for the past 10 Years (both Annual and Quarterly)

(All values are in $ million)

Year Q1 Q2 Q3 Q4 Fiscal Year
2021 $177.67
2020 $137.58 $144.08 $203.38 $137.48 $137.58
2019 $109.64 $151.09 $151.09 $142.23 $109.64
2018 $144.65 $143.2 $135.58 $133.92 $111.47
2017 $136.34 $129.47 $126.44 $121.04 $100.67
2016 $117.13 $117.34 $111.04 $104.39 $86.44
2015 $90.06 $90.6 $89.45 $86.15 $90.06
2014 $85.4 $82.63 $86.65 $87.49 $85.4
2013 $85.61 $64.67 $59.13 $57.17 $85.61
2012 $56.07 $52.37 $50.37 $63.73 $56.07
2011 $62.41 $66.58 $67.72 $84.56 $62.41
2010 $82.16 $80.33 $86.48 $82.16

Business Profile of CryoLife, Inc.

Sector: Healthcare
Industry: Medical Devices
CryoLife, Inc. manufactures, processes, and distributes medical devices and implantable human tissues worldwide. It offers BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X prosthetic aortic and mitral heart valve, and On-X ascending aortic prosthesis; cardiac preservation services; PhotoFix, a bovine pericardial patch; and E-vita OPEN PLUS and E-vita OPEN NEO, a hybrid stent graft system. The company also provides E-xtra DESIGN ENGINEERING products for the treatment of aortic vascular diseases; E-nside, an off-the-shelf stent graft for the treatment of thoraco-abdominal disease; E-vita THORACIC 3G for the endovascular treatment of thoracic aortic aneurysms; E-nya, a thoracic stent graft system for the minimally invasive repair of lesions of the descending aorta; E-ventus BX, a balloon-expandable peripheral stent graft for the endovascular treatment of renal and pelvic arteries; E-liac to treat aneurysmal iliac arteries, and aneurysmal iliac side branches; and E-tegra, an abdominal aortic aneurysms stent graft system. In addition, it offers synthetic vascular grafts for use in open aortic and peripheral vascular surgical procedures; PerClot, an absorbable powdered hemostat for use in surgical procedures; and cardiac laser therapy products, such as SolarGen 2100s Console and SoloGrip III disposable handpieces. Further, the company sells CryoVein femoral vein and CryoArtery femoral artery vascular preservation services; CarbonAid CO2 diffusion catheters and Chord-X ePTFE sutures for mitral chordal replacement; and ascyrus medical dissection stents, as well as offers pyrolytic carbon coating services to other medical device manufacturers. The company serves physicians, hospitals, and other healthcare facilities, as well as cardiac, vascular, thoracic, and general surgeons. CryoLife, Inc. was founded in 1984 and is headquartered in Kennesaw, Georgia.